FGEN PE Ratio & Valuation,Is FGEN Overvalued

FGEN Relative Valuation

FGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FGEN is overvalued; if below, it's undervalued.

Historical Valuation

FibroGen Inc (FGEN) is now in the Fair zone, suggesting that its current forward PS ratio of 5.41 is considered Fairly compared with the five-year average of -5.23. The fair price of FibroGen Inc (FGEN) is between 2.65 to 14.12 according to relative valuation methord.

Relative Value

Fair Zone

2.65-14.12

Current Price：8.38

Fair

-0.50

0.65

EV/EBITDA

FibroGen Inc. (FGEN) has a current EV/EBITDA of 0.65. The 5-year average EV/EBITDA is -4.60. The thresholds are as follows: Strongly Undervalued below -24.51, Undervalued between -24.51 and -14.55, Fairly Valued between 5.36 and -14.55, Overvalued between 5.36 and 15.32, and Strongly Overvalued above 15.32. The current Forward EV/EBITDA of 0.65 falls within the Historic Trend Line -Fairly Valued range.

0.64

EV/EBIT

FibroGen Inc. (FGEN) has a current EV/EBIT of 0.64. The 5-year average EV/EBIT is -3.89. The thresholds are as follows: Strongly Undervalued below -14.05, Undervalued between -14.05 and -8.97, Fairly Valued between 1.19 and -8.97, Overvalued between 1.19 and 6.27, and Strongly Overvalued above 6.27. The current Forward EV/EBIT of 0.64 falls within the Historic Trend Line -Fairly Valued range.

5.41

FibroGen Inc. (FGEN) has a current PS of 5.41. The 5-year average PS is 5.44. The thresholds are as follows: Strongly Undervalued below -3.82, Undervalued between -3.82 and 0.81, Fairly Valued between 10.07 and 0.81, Overvalued between 10.07 and 14.70, and Strongly Overvalued above 14.70. The current Forward PS of 5.41 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

FibroGen Inc. (FGEN) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.08. The thresholds are as follows: Strongly Undervalued below -19.86, Undervalued between -19.86 and -11.47, Fairly Valued between 5.31 and -11.47, Overvalued between 5.31 and 13.70, and Strongly Overvalued above 13.70. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

FibroGen Inc. (FGEN) has a current P/FCF of 0.00. The 5-year average P/FCF is -8.20. The thresholds are as follows: Strongly Undervalued below -45.32, Undervalued between -45.32 and -26.76, Fairly Valued between 10.36 and -26.76, Overvalued between 10.36 and 28.92, and Strongly Overvalued above 28.92. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

FibroGen Inc (FGEN) has a current Price-to-Book (P/B) ratio of -2.02. Compared to its 3-year average P/B ratio of -10.14 , the current P/B ratio is approximately -80.11% higher. Relative to its 5-year average P/B ratio of -1.25, the current P/B ratio is about 60.89% higher. FibroGen Inc (FGEN) has a Forward Free Cash Flow (FCF) yield of approximately -50.41%. Compared to its 3-year average FCF yield of -244.31%, the current FCF yield is approximately -79.36% lower. Relative to its 5-year average FCF yield of -147.40% , the current FCF yield is about -65.80% lower.

-2.02

P/B

Median3y

-10.14

Median5y

-1.25

-50.41

FCF Yield

Median3y

-244.31

Median5y

-147.40

Competitors Valuation Multiple

The average P/S ratio for FGEN's competitors is 4.63, providing a benchmark for relative valuation. FibroGen Inc Corp (FGEN) exhibits a P/S ratio of 5.41, which is 16.88% above the industry average. Given its robust revenue growth of 774.80%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of FGEN decreased by 36.69% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 123.00K to 1.08M.

The secondary factor is the Margin Expansion, contributed -96.89%to the performance.

Overall, the performance of FGEN in the past 1 year is driven by Revenue Growth. Which is more sustainable.

774.80%

123.00K → 1.08M

Revenue Growth

-96.89%

-39.26K → -1.22K

Margin Expansion

-714.60%

0.11 → -0.66

P/E Change

-36.69%

13.24 → 8.38

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is FibroGen Inc (FGEN) currently overvalued or undervalued?

What is FibroGen Inc (FGEN) fair value?

FGEN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of FibroGen Inc (FGEN) is between 2.65 to 14.12 according to relative valuation methord.

How does FGEN's valuation metrics compare to the industry average?

What is the current P/B ratio for FibroGen Inc (FGEN) as of Dec 15 2025?

As of Dec 15 2025, FibroGen Inc (FGEN) has a P/B ratio of -2.02. This indicates that the market values FGEN at -2.02 times its book value.

What is the current FCF Yield for FibroGen Inc (FGEN) as of Dec 15 2025?

As of Dec 15 2025, FibroGen Inc (FGEN) has a FCF Yield of -50.41%. This means that for every dollar of FibroGen Inc’s market capitalization, the company generates -50.41 cents in free cash flow.

What is the current Forward P/E ratio for FibroGen Inc (FGEN) as of Dec 15 2025?

As of Dec 15 2025, FibroGen Inc (FGEN) has a Forward P/E ratio of -0.50. This means the market is willing to pay $-0.50 for every dollar of FibroGen Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for FibroGen Inc (FGEN) as of Dec 15 2025?

As of Dec 15 2025, FibroGen Inc (FGEN) has a Forward P/S ratio of 5.41. This means the market is valuing FGEN at $5.41 for every dollar of expected revenue over the next 12 months.

FGEN Valuation